2026年2月27日,一家印度公司Zenex动物健康公司获得荷兰动物自然营养公司VievePharm的多数股权,以扩大其在欧洲的存在并支持减少抗生素的目标。 Zenex Animal Health, an Indian company, acquired a majority stake in Dutch natural animal nutrition firm VievePharm on February 27, 2026, to expand its European presence and support antibiotic reduction goals.

Zenex动物健康公司是一家设在印度的公司,由Mollys PE提供支持。 该公司在荷兰的VievePharm公司获得大部分股权,该公司是天然动物营养专家,其金额未披露。 Zenex Animal Health, an India-based company backed by Multiples PE, has acquired a majority stake in Netherlands-based VievePharm, a natural animal nutrition specialist, for an undisclosed amount. 该协议于2026年2月27日宣布, 扩大Zenex在西欧的生产和销售规模, 并强化其草药及植物动物健康产品组合。 The deal, announced on February 27, 2026, expands Zenex’s manufacturing and sales presence in Western Europe and strengthens its portfolio of herbal and phytogenic animal health products. VievePharm以其肉毒杆菌技术和欧盟分销网络著称,为25个国家的牲畜、黄蜂和宠物市场提供服务。 VievePharm, known for its bolus technology and EU distribution network, serves livestock, equine, and pet care markets across 25 countries. 该收购支持Zenex的全球增长战略,并与欧盟的农场与福克(Fork)目标保持一致,即到2030年将兽医抗生素使用量削减50%。 The acquisition supports Zenex’s global growth strategy and aligns with the EU’s Farm to Fork goal to cut veterinary antibiotic use by 50% by 2030. 荷兰枢纽将成为出口Zenex天然产品的基地。 The Netherlands hub will serve as a base for exporting Zenex’s natural products.